With just two weeks until IBM unveils its second-quarter figures on July 22, the stock is navigating a curious mix of technical momentum, strategic buzz, and lingering macroeconomic caution. The shares closed at €251.50 on Friday, a level that sits 14.12% below the 52-week high of €292.85 set on June 1, yet marks a 38.71% recovery from the May low of €181.32. The implied annual volatility over the past 30 days has climbed to 60.41%, underscoring a stock that has lurched from trough to near-peak and back again in the space of a few months.
The recent rally owes much to a string of announcements that have shifted sentiment. On June 26, IBM unveiled a partnership with Deloitte and Red Hat dubbed Lightwell, aimed at shielding software supply chains from automated cyberattacks. Deloitte will handle integration and risk services, while Red Hat and IBM contribute open-source security engineering to deliver verified patches directly into production systems with minimal disruption. The launch has kept analysts engaged through early July and helped propel the shares: over a recent seven-session stretch, IBM rose 3.39%, and the entire week ended with a 5.76% advance.
The alliance also caught the attention of BlackRock, which has included IBM among the 30 most important names in the global artificial-intelligence market. That recognition dovetails with a broader reassessment on Wall Street. On June 23, JPMorgan analyst Brian Essex upgraded IBM from Neutral to Overweight, raising the price target from $270 to $291. Essex cited surging demand for software services driven by accelerated AI adoption, arguing that the market underestimates how strongly that segment will boost recurring revenue, margins, and cash flow in the second half. Software already accounts for about 45% of IBM’s total revenue and roughly two-thirds of its profit.
Technical indicators reflect the renewed buying pressure. IBM trades 13.37% above its 50-day moving average of €221.83 and 6.36% above the 200-day average of €236.47. The 14-day relative strength index stands at 62, comfortably below the overbought threshold. Yet the stock remains 14.12% below its June peak, and the modest year-to-date advance of 1.15% (and a 12-month gain of just 0.78%) masks the violent swings beneath the surface.
Should investors sell immediately? Or is it worth buying IBM?
The bigger narrative, however, goes beyond near-term price action. IBM is in the early stages of a decade-long bet on quantum computing. It has pledged more than $10 billion over the next five years toward research, manufacturing, acquisitions, and ecosystem development, aiming to deliver the world’s first large-scale, fault-tolerant quantum computer—named Starling—by 2029. That system promises 20,000 times more operations than current machines. While the ambition captured headlines and fueled the rally from the May trough, the quantum story remains a multiyear thesis with no financial impact on next month’s earnings. CEO Arvind Krishna is expected to provide an update on the quantum roadmap alongside the quarterly results.
The real test lies in whether the consulting division’s recent softness was a temporary blip or a persistent drag. The July 22 report will also clarify whether the consulting pipeline is recovering, and how the broader IT spending environment is evolving. In the absence of fresh catalysts, the analyst consensus price target of roughly €256.83 offers only 2.1% upside from Friday’s close—a sign that the market is waiting for proof before betting more aggressively.
Until then, traders are left with technical support lines. The 50-day average near €222 could provide a floor if momentum fades, while the 200-day average around €236 might act as a pivot. A test of the €292.85 high seems unlikely without a substantive trigger, but the stock has already demonstrated its capacity for double-digit weekly swings. With volatility elevated and a critical earnings date approaching, IBM’s path over the next fortnight will be shaped as much by positioning and psychology as by the fundamentals still under wraps.
Ad
IBM Stock: Buy or Sell?! New IBM Analysis from July 6 delivers the answer:
The latest IBM figures speak for themselves: Urgent action needed for IBM investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 6.
IBM: Buy or sell? Read more here...
